Search

Your search keyword '"Maria, Ruggero"' showing total 553 results

Search Constraints

Start Over You searched for: Author "Maria, Ruggero" Remove constraint Author: "Maria, Ruggero" Language english Remove constraint Language: english
553 results on '"Maria, Ruggero"'

Search Results

1. Correction to: Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres

2. Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres

3. The 1+Million Genomes Minimal Dataset for Cancer

4. Author Correction: Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B

6. Correction to: L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fbrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients

7. L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fibrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients

8. Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems

9. Apoptotic cell death in disease—Current understanding of the NCCD 2023

12. Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B

13. Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51

14. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer

15. An organoid model of colorectal circulating tumor cells with stem cell features, hybrid EMT state and distinctive therapy response profile

16. A real-time integrated framework to support clinical decision making for covid-19 patients

17. Oncolytic virus and CAR-T cell therapy in solid tumors.

18. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy

19. CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin

20. Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51

21. Advancements in 3D In Vitro Models for Colorectal Cancer.

23. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

24. Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery

26. Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant

27. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma

28. Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer

29. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

30. Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection

32. A moonshot approach toward the management of cancer patients in the COVID-19 time: what have we learned and what could the Italian network of cancer centers (Alliance Against Cancer, ACC) do after the pandemic wave?

33. A pre-existing population of ZEB2+ quiescent cells with stemness and mesenchymal features dictate chemoresistance in colorectal cancer

35. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

40. A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells

41. A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors

44. Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases

45. The autophagic protein FYCO1 controls TNFRSF10/TRAIL receptor induced apoptosis and is inactivated by CASP8 (caspase 8).

47. Renal cancer: new models and approach for personalizing therapy

48. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer

49. Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer

50. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models

Catalog

Books, media, physical & digital resources